Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial - PubMed (original) (raw)
Randomized Controlled Trial
Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial
Vera Bittner et al. J Am Coll Cardiol. 2015.
Abstract
Background: It is unclear whether achieving multiple risk factor (RF) goals through protocol-guided intensive medical therapy is feasible or improves outcomes in type 2 diabetes mellitus.
Objectives: This study sought to quantify the relationship between achieved RF goals in the BARI 2D (Bypass Angioplasty Investigation Revascularization 2 Diabetes) trial and cardiovascular events/survival.
Methods: We performed a nonrandomized analysis of survival/cardiovascular events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure [systolic <130 mm Hg; diastolic <80 mm Hg], glycosylated hemoglobin <7%) in BARI 2D. Cox models with time-varying number of RFs in control were adjusted for baseline number of RFs in control, clinical characteristics, and trial randomization assignments.
Results: In 2,265 patients (mean age 62 years, 29% women) followed up for 5 years, the mean ± SD number of RFs in control improved from 3.5 ± 1.4 at baseline to 4.2 ± 1.3 at 5 years (p < 0.0001). The number of RFs in control during the trial was strongly related to death (global p = 0.0010) and the composite of death, myocardial infarction, and stroke (global p = 0.0035) in fully adjusted models. Participants with 0 to 2 RFs in control during follow-up had a 2-fold higher risk of death (hazard ratio: 2.0; 95% confidence interval: 1.3 to 3.3; p = 0.0031) and a 1.7-fold higher risk of the composite endpoint (hazard ratio: 1.7; 95% confidence interval: 1.2 to 2.5; p = 0.0043), compared with those with 6 RFs in control.
Conclusions: Simultaneous control of multiple RFs through protocol-guided intensive medical therapy is feasible and relates to cardiovascular morbidity and mortality in patients with coronary disease and type 2 diabetes mellitus. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305).
Keywords: blood pressure; cholesterol; coronary heart disease; diabetes mellitus; glycosylated hemoglobin A; smoking.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1. Distribution of the Number of RFs In Control: Baseline to Year 5
The numbers of RFs in control are shown at baseline and for each year of the trial. Over time, the proportion of participants with 4 or more RFs in control increased while the proportion with fewer RFs in control declined. RF = risk factor.
Figure 2. Hazard Associated With Individual RFs Out of Control/Out of Target Range
Multivariable-adjusted hazard ratios (95% CI) are shown for individual RFs out of target range. RFs in control/in target range for this exploratory analysis were defined as: non-HDL-C <130 mg/dl, TG <150 mg/dl, 110 mm Hg< SBP <140 mm Hg, DBP <80 mm Hg, 65%< HbA1c <7.5%, nonsmoker. Cox models were adjusted for number of total lesions, abnormal LVEF, myocardial jeopardy index, history of prior revascularization, age, sex, race/ethnicity, country, and trial strata. DBP = diastolic blood pressure; HbA1c = glycosylated hemoglobin; LVEF = left ventricular ejection fraction; MI = myocardial infarction; non-HDL-C = high-density lipoprotein cholesterol; RF = risk factor; SBP = systolic blood pressure; TG = triglycerides.
Central Illustration. Cardiac RF Control Improves Survival: Number of RFs in Control and Outcomes
The number of RFs in control is plotted against mortality (A and B) and against CVD events (C and D). In panels A and C, RFs in control are defined on the basis of the BARI 2D protocol (main analysis). A J-shape is evident: individuals with 6 RFs in control have a numerically higher risk of events than those with 5 RFs in control. In panels B and D, “optimal ranges” are defined for systolic and diastolic BP and HbA1c. A J-shape is no longer evident and the risk gradient comparing 6 versus 0 to 2 RFs in control is steeper. BP = blood pressure; CVD = cardiovascular disease; HbA1c = glycosylated hemoglobin; HR = hazard ratio; MI = myocardial infarction; RF = risk factor.
Comment in
- Why Optimal Medical Therapy Should Be a Universal Standard of Care.
Maron DJ, Boden WE. Maron DJ, et al. J Am Coll Cardiol. 2015 Aug 18;66(7):774-776. doi: 10.1016/j.jacc.2015.06.018. J Am Coll Cardiol. 2015. PMID: 26271058 Free PMC article. No abstract available.
Similar articles
- Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK; BARI 2D Study Group. Tamis-Holland JE, et al. J Am Coll Cardiol. 2013 Apr 30;61(17):1767-76. doi: 10.1016/j.jacc.2013.01.062. Epub 2013 Feb 28. J Am Coll Cardiol. 2013. PMID: 23500245 Clinical Trial. - Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.
Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group. Dagenais GR, et al. J Am Coll Cardiol. 2013 Feb 19;61(7):702-11. doi: 10.1016/j.jacc.2012.11.036. J Am Coll Cardiol. 2013. PMID: 23410541 Free PMC article. Clinical Trial. - Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
Sobel BE, Frye R, Detre KM; Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Sobel BE, et al. Circulation. 2003 Feb 4;107(4):636-42. doi: 10.1161/01.cir.0000048897.03553.e4. Circulation. 2003. PMID: 12566379 Review.
Cited by
- Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus.
Song DK, Hong YS, Sung YA, Lee H. Song DK, et al. PLoS One. 2024 Feb 29;19(2):e0299035. doi: 10.1371/journal.pone.0299035. eCollection 2024. PLoS One. 2024. PMID: 38422102 Free PMC article. - Association between malnutrition and stroke-associated pneumonia in patients with ischemic stroke.
Li D, Liu Y, Jia Y, Yu J, Li F, Li H, Ye L, Liao X, Wan Z, Zeng Z, Cao Y. Li D, et al. BMC Neurol. 2023 Aug 3;23(1):290. doi: 10.1186/s12883-023-03340-1. BMC Neurol. 2023. PMID: 37537542 Free PMC article. - Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America.
Ruiz-Beltran AM, Alcaraz-Guzman A, Campos-Franco DR, Jimenez-Lopez CD, Ruiz-Beltran SM, Delgadillo-Rodriguez HE. Ruiz-Beltran AM, et al. High Blood Press Cardiovasc Prev. 2023 Mar;30(2):183-189. doi: 10.1007/s40292-023-00560-x. Epub 2023 Feb 3. High Blood Press Cardiovasc Prev. 2023. PMID: 36735221 - Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial.
Mathew RO, Maron DJ, Anthopolos R, Fleg JL, O'Brien SM, Rockhold FW, Briguori C, Roik MF, Mazurek T, Demkow M, Malecki R, Ye Z, Kaul U, Miglinas M, Stone GW, Wald R, Charytan DM, Sidhu MS, Hochman JS, Bangalore S. Mathew RO, et al. Circ Cardiovasc Qual Outcomes. 2022 Oct;15(10):e008995. doi: 10.1161/CIRCOUTCOMES.122.008995. Epub 2022 Oct 4. Circ Cardiovasc Qual Outcomes. 2022. PMID: 36193750 Free PMC article. Clinical Trial. - Prevalence of coronary calcification on preoperative computed tomography and its management in thoracic surgery.
Machino R, Shimoyama K, Oku K, Yamasaki K, Tagawa T. Machino R, et al. Surg Today. 2023 Jan;53(1):62-72. doi: 10.1007/s00595-022-02532-5. Epub 2022 Jun 13. Surg Today. 2023. PMID: 35695922 Free PMC article.
References
- Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–2398. - PubMed
- Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393. - PubMed
- Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
- U01 HL061746/HL/NHLBI NIH HHS/United States
- U01 HL061748/HL/NHLBI NIH HHS/United States
- U01 HL061744/HL/NHLBI NIH HHS/United States
- U01 HL063804/HL/NHLBI NIH HHS/United States
- R21 HL121495/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical